Sumanirole Pharmacia.
Sumanirole is a dopamine D2 agonist under development by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of Parkinson's disease. The compound is currently undergoing phase II trials in Japan and phase III clinical trials in the US.
de Paulis
Tomas
T
Psychiatry Department, MCN AA-2213, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Tomas.dePaulis@vanderbilt.edu
D000978:Antiparkinson Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D018491:Dopamine Agonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D017448:Receptors, Dopamine D2 / Q000819:agonists; D013329:Structure-Activity Relationship
D000978:Antiparkinson Agents; D001562:Benzimidazoles; D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; C108539:U 95666E